Goa unveils lifesaving therapies pricing policy

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-16 09:46 GMT | Update On 2025-08-16 09:46 GMT

Panaji: In a bold move set to transform healthcare access, the Goa government has launched pricing policy to make lifesaving therapies more affordable and accessible.

Health Minister Vishwajit Rane unveiled the groundbreaking Goa’s Pricing Policy for Innovative Lifesaving Therapies on Thursday in Panaji, calling it a “landmark moment for healthcare in Goa”.

“This is not just a policy. It's a promise of better health and a brighter future for all,” the minister added.

Under the policy, the state government will negotiate lower drug and equipment prices with pharmaceutical companies to benefit citizens with rare genetic disorders, cancer and autoimmune diseases, said officials.

He said this “pioneering” policy ensures fair and sustainable pricing for critical treatments, the minister said.

Read also: No Clear Winner: Three Dual-Drug Hypertension Therapies Work Equally Well in Indian Adults, TOPSPIN Trial Finds

“It will make life-saving therapies far more affordable and accessible, giving new hope to patients and families across the state,” the minister said.

The initiative will reduce the financial burden on patients, improve access to cutting-edge treatments and set a national benchmark for equitable healthcare, said Rane.

Read also: Chemists' Body Warns of 55% Rise in Drug Abuse, Calls for Ban on 10-Minute Prescription Drug Delivery

As per PTI, a senior health department official said that under the policy, the state will procure drugs, medical equipment and diagnostics from pharma companies at a lower negotiated rate, enabling fair allocation of budget among more patients or supporting a longer duration for therapies.

He said a committee chaired by the Additional Secretary or Joint Secretary of the Goa government and comprising the Dean of Goa Medical College and the State Director of Health Services has been constituted to recommend appropriate pricing for government approval.

Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Goa unveils lifesaving therapies pricing policy

Similar News

JnJ bags USFDA nod for bladder cancer treatment Inlexzo

Indian Pharma Market Grows 8.7% in August, Records Rs 20,984 Crore Sales: PharmaTrac

NPPA Clarifies Pharma Data Tender Terms, Technical Presentations on Sept 19

Active Pharm Chemicals Loses Rs 2.17 Crore in API Supply Fraud, 4 Booked

Chemist Body Seeks Transition Period, GST Input Adjustment After Tax Cut, Writes to CM

Strides Pharma Science Singapore arm, Kenox Pharma partner to develop multiple nasal spray products for US

Novartis to buy Tourmaline Bio for USD 1.4 billion

Eli lilly, Circle Pharma ink pact to further enhance AI/ML capabilities